Lupin’s Ankleshwar facility receives EIR from US FDA
Global pharma major Lupin announced that it has received the Establishment Inspection Report (EIR) from the United States Food and Drug Administration (US FDA) for its Ankleshwar facility in Gujarat, India, following closure of a product- specific Pre-Approval Inspection from March 2 to March 7, 2026.
Nilesh Gupta, Managing Director, Lupin, stated, “We are pleased to receive the EIR from the US FDA for our Ankleshwar facility. This outcome reflects our continued focus on quality excellence and regulatory compliance, reinforcing our commitment to delivering safe and effective medicines to patients worldwide.”
The post Lupin’s Ankleshwar facility receives EIR from US FDA appeared first on Express Pharma.
Apa Reaksi Anda?
Suka
0
Kurang Suka
0
Setuju
0
Tidak Setuju
0
Bagus
0
Berguna
0
Hebat
0
Edusehat
Platform Edukasi Online Untuk Komunitas Kesehatan Agar Mendapatkan Informasi Dan Pengetahuan Terbaru Tentang Kesehatan Dari Nasional Maupun Internasional. ||
An online education platform for the health community to obtain the latest information and knowledge about health from both national and international sources.
